Cancer Treatment Centers of America® in Arizona Purchases BSD-2000 Hyperthermia System from BSD Medical

  Cancer Treatment Centers of America® in Arizona Purchases BSD-2000
  Hyperthermia System from BSD Medical

Business Wire

SALT LAKE CITY -- November 26, 2012

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (,
a leading provider of medical systems that utilize targeted heat therapy to
treat cancer, announced today that the Cancer Treatment Centers of America^®
(CTCA) at Western Regional Medical Center (WRMC), located in Goodyear,
Arizona, has purchased a BSD-2000 Hyperthermia System (BSD-2000). WRMC serves
the Western United States, including the major metropolitan areas of Phoenix,
Denver, Los Angeles, Las Vegas, Seattle, Portland and Albuquerque. This will
be the eighth BSD Hyperthermia system purchased by CTCA^®.

WRMC is a state-of-the-art, all-digital cancer hospital that provides advanced
cancer treatments, world-class technologies and integrative therapies under
one roof. The 213,000-square-foot facility is located on a 25-acre site, which
is part of the Phoenix metropolitan area. Like the other CTCA cancer
hospitals, WRMC provides the most advanced therapeutic resources in cancer

CTCA is a network of hospitals and one of the premier providers of cancer care
in the world. CTCA physicians specialize in treating many types of cancer,
including complex and advanced stage cases. CTCA is committed to
revolutionizing cancer care by providing the most advanced and effective
cancer treatments and integrative therapies available in order to treat the
cancer and improve the patient’s treatment experience and quality of life. The
CTCA hospitals were recently recognized by the Commission on Cancer of the
American College of Surgeons as "offering the very best in cancer care."

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size, and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at

About Cancer Treatment Centers of America®

Cancer Treatment Centers of America, Inc. (CTCA) is a national network of
hospitals focusing on complex and advanced stage cancer. CTCA offers a
comprehensive, fully integrated approach to cancer treatment and serves
patients from all 50 states at facilities located in Atlanta, Chicago,
Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of
care and Patient Empowerment Medicine®, CTCA provides patients with
information about cancer and their treatment options so they can control their
treatment decisions. For more information about CTCA, go to

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.


BSD Medical Corporation
Dennis Gauger, 801-972-5555
fax: 801-972-5930
Press spacebar to pause and continue. Press esc to stop.